Plasma lipoprotein profile in the male cynomolgus monkey under normal, hypogonadal, and combined androgen blockade conditions

Journal of Clinical Endocrinology and Metabolism

Volumn 89, Issue 4, 2004, Pages 1849-1857

  Leblanc, Mathias ^a   Bélanger, Marie Claire ^a   Julien, Pierre ^a   Tchernof, André ^a   Labrie, Claude ^a   Bélanger, Alain ^a   Labrie, Fernand ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTANEDIOL; ANDROSTANOLONE; ANDROSTERONE; GLUCURONIDE; HIGH DENSITY LIPOPROTEIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; PRASTERONE; PRASTERONE SULFATE;

ANDROGEN METABOLISM; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; LIPID METABOLISM; LIPOPROTEIN BLOOD LEVEL; MALE; MESENTERY; MONKEY; NONHUMAN; ORCHIECTOMY; PRIORITY JOURNAL; STEROID BLOOD LEVEL;

ADIPOSE TISSUE; ANDROGEN ANTAGONISTS; ANDROGENS; ANIMALS; APOLIPOPROTEINS B; BODY COMPOSITION; DIHYDROTESTOSTERONE; DRUG ADMINISTRATION SCHEDULE; FLUTAMIDE; HYPOGONADISM; LIPOPROTEINS; LIPOPROTEINS, LDL; MACACA FASCICULARIS; MALE; MESENTERY; ORCHIECTOMY; TESTOSTERONE;

ANIMALIA; MACACA FASCICULARIS;

EID: 11144354142     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.2003-031233     Document Type: Article

References (41)

1. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ 2003 Cancer statistics, 2003. CA Cancer J Clin 53:5-26
2. Huggins CHC 1941 Studies of prostatic cancer. I. Effect of castration, estrogen and androgen injections on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293
3. Faure N, Labrie F, Lemay A, Belanger A, Gourdeau Y, Laroche B, Robert G 1982 Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LHRH) agonist in adult men. Fertil Steril 37:416-424
4. Labrie F, Bélanger A, Cusan L, Séguin C, Pelletier G, Kelly PA, Reeves JJ, Lefebvre F-A, Lemay A, Gourdeau Y, Raynaud J-P 1980 Antifertility effects of LHRH agonists in the male. J Androl 1:209-228
5. Labrie F, Dupont A, Bélanger A 1985 Complete androgen blockade for the treatment of prostate cancer. In: de Vita VT, Hellman S, Rosenberg SA, eds. Important advances in oncology. Philadelphia: J B Lippincott; 193-217
6. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ 1989 A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424
7. Bennett CL, Tosteson TD, Schmitt B, Weinberg PD, Ernstoff MS, Ross SD 1999 Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: a meta-analysis of nine published randomized controlled trials and 4128 patients using Flutamide. Prostate Cancer Prostatic Dis 2:4-8
8. Labrie F, Candas B 2000 Androgen blockade in prostate cancer. Lancet 356: 341-342
9. Labrie F 2002 Androgen blockade in prostate cancer in 2002: major benefits on survival in localized disease. Mol Cell Endocrinol 198:77-87
10. Labrie F, Luu-The V, Labrie C, Simard J 2001 DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol 22:185-212
11. Tchernof A, Labrie F, Belanger A, Prud'homme D, Bouchard C, Tremblay A, Nadeau A, Despres JP 1997 Relationships between endogenous steroid hormone, sex hormone-binding globulin and lipoprotein levels in men: contribution of visceral obesity, insulin levels and other metabolic variables. Atherosclerosis 133:235-244
12. Xu T, Wang X, Hou S, Zhu J, Zhang X, Huang X 2002 Effect of surgical castration on risk factors for arteriosclerosis of patients with prostate cancer. Chin Med J (Engl) 115:1336-1340
13. Moorjani S, Dupont A, Labrie F, Lupien PJ, Gagne C, Brun D, Giguere M, Belanger A, Cusan L 1988 Changes in plasma lipoproteins during various androgen suppression therapies in men with prostatic carcinoma: effects of orchiectomy, estrogen, and combination treatment with luteinizing hormone-releasing hormone agonist and flutamide. J Clin Endocrinol Metab 66:314-322
14. Goldberg RB, Rabin D, Alexander AN, Doelle GC, Getz GS 1985 Suppression of plasma testosterone leads to an increase in serum total and high density lipoprotein cholesterol and apoproteins A-I and B. J Clin Endocrinol Metab 60:203-207
15. Bagatell CJ, Bremner WJ 1995 Androgen and progestagen effects on plasma lipids. Prog Cardiovasc Dis 38:255-271
16. Moorjani S, Dupont A, Labrie F, Lupien PJ, Brun D, Gagne C, Giguere M, Belanger A 1987 Increase in plasma high-density lipoprotein concentration following complete androgen blockage in men with prostatic carcinoma. Metabolism 36:244-250
17. Bagatell CJ, Knopp RH, Rivier JE, Bremner WJ 1994 Physiological levels of estradiol stimulate plasma high density lipoprotein2 cholesterol levels in normal men. J Clin Endocrinol Metab 78:855-861
18. Ordovas JM 1998 Fast ultracentrifugation methods for the separation of plasma lipoproteins. Methods Mol Biol 110:93-103
19. Connelly PW, Poapst M, Davignon J, Lussier-Cacan S, Reeder B, Lessard R, Hegele RA, Csima A 1999 Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Canadian Heart Health Surveys Research Group. Can J Cardiol 15:409-418
20. Kather H, Schroder F, Simon B 1982 Microdetermination of glycerol using bacterial NADH-linked luciferase. Clin Chim Acta 120:295-300
21. Taskinen MR, Nikkila EA 1977 Lipoprotein lipase activity in adipose tissue and in postheparin plasma in human obesity. Acta Med Scand 202:399-408
22. Leblanc M, Labrie C, Belanger A, Candas B, Labrie F 2002 Pharmacokinetics of oral dehydroepiandrosterone (DHEA) in the ovariectomised cynomolgus monkey. J Steroid Biochem Mol Biol 81:159-164
23. Labrie F, Belanger A, Cusan L, Candas B 1997 Physiological changes in dehydroepiandrosterone are not reflected by serum levels of active androgens and estrogens but of their metabolites: intracrinology. J Clin Endocrinol Metab 82:2403-2409
24. Greger NG, Insull Jr W, Probstfield JL, Keenan BS 1990 High-density lipoprotein response to 5-α-dihydrotestosterone and testosterone in Macaca fascicularis: a hormone-responsive primate model for the study of atherosclerosis. Metabolism 39:919-924
25. Labrie F 1991 Intracrinology. Mol Cell Endocrinol 78:C113-C118
26. Weidemann W, Hanke H 2002 Cardiovascular effects of androgens. Cardiovasc Drug Rev 20:175-198
27. Gupta SV, Khosla P 2001 Palmitic and stearic acids similarly affect plasma lipoprotein metabolism in cynomolgus monkeys fed diets with adequate levels of linoleic acid. J Nutr 131:2115-2120
28. Smith MR, Finkelstein JS, McGovern FJ, Zietman AL, Fallon MA, Schoenfeld DA, Kantoff PW 2002 Changes in body composition during androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab 87:599-603
29. Elbers JM, Asscheman H, Seidell JC, Gooren LJ 1999 Effects of sex steroid hormones on regional fat depots as assessed by magnetic resonance imaging in transsexuals. Am J Physiol 276:E317-E325
30. Mohamed-Ali V, Pinkney JH, Coppack SW 1998 Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord 22:1145-1158
31. Labrie F, Luu-The V, Labrie C, Bélanger A, Simard J, Lin SX, Pelletier G 2003 Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr Rev 24:152-182
32. Labrie F 1995 Endocrine therapy of prostate cancer: optimal form and timing. J Clin Endocrinol Metab 80:1066-1071
33. Guillemette C, Hum DW, Belanger A 1996 Levels of plasma C19 steroids and 5 α-reduced C19 steroid glucuronides in primates, rodents, and domestic animals. Am J Physiol 271:E348-E353
34. Albert C, Barbier O, Vallee M, Beaudry G, Belanger A, Hum DW 2000 Distribution of uridine diphosphate-glucuronosyltransferase (UGT) expression and activity in cynomolgus monkey tissues: evidence for differential expression of steroid-conjugating UGT enzymes in steroid target tissues. Endocrinology 141:2472-2480
35. Briggs MR, Yokoyama C, Wang X, Brown MS, Goldstein JL 1993 Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. I. Identification of the protein and delineation of its target nucleotide sequence. J Biol Chem 268:14490-14496
36. Wang X, Briggs MR, Hua X, Yokoyama C, Goldstein JL, Brown MS 1993 Nuclear protein that binds sterol regulatory element of low density lipoprotein receptor promoter. II. Purification and characterization. J Biol Chem 268:14497-14504
37. Croston GE, Milan LB, Marschke KB, Reichman M, Briggs MR 1997 Androgen receptor-mediated antagonism of estrogen-dependent low density lipoprotein receptor transcription in cultured hepatocytes. Endocrinology 138: 3779-3786
38. Borradaile NM, de Dreu LE, Wilcox LJ, Edwards JY, Huff MW 2002 Soya phytoestrogens, genistein and daidzein, decrease apolipoprotein B secretion from HepG2 cells through multiple mechanisms. Biochem J 366:531-539
39. Anderson LA, McTernan PG, Harte AL, Barnett AH, Kumar S 2002 The regulation of HSL and LPL expression by DHT and flutamide in human subcutaneous adipose tissue. Diabetes Obes Metab 4:209-213
40. De Pergola G 2000 The adipose tissue metabolism: role of testosterone and dehydroepiandrosterone. Int J Obes Relat Metab Disord 24(Suppl 2):S59-S63
41. Sourla A, Martel C, Labrie C, Labrie F 1998 Almost exclusive androgenic action of dehydroepiandrosterone in the rat mammary gland. Endocrinology 139:753-764